

How GARDP's REVIVE platform is providing open-access tools and resources for the antimicrobial R&D community

Astrid Pentz-Murr, Alexandra Santu, Shirine Derakhshani, Laura JV Piddock

Key words: Resources, antimicrobial, drug discovery & development

Background

With limited funding across the antibiotic pipeline, companies and academia are abandoning and deprioritizing antimicrobial research and development (R&D), the Global Antibiotic Research & Development Partnership (GARDP) Scientific Affairs team is actively working to prevent the loss of valuable knowledge and expertise.

Materials

We are doing this by facilitating learning, connecting people, and sharing knowledge; our outputs are available on REVIVE (revive.gardp.org). To help streamline the development of urgently needed treatments, we gather knowledge and skills from the antimicrobial R&D community and make them freely available to all via webinars, peer-reviewed Viewpoint articles, an open-access online conference and other resources.

Results

Recent [REVIVE webinars](#) addressed topics such as SAR optimization and QSAR in antimicrobial drug discovery and clinical trial platforms for new and neglected antimicrobials. Another webinar series, the [AMR Discussions](#), hosts panel discussions on various topics related to AMR, e.g., most recently, on market interventions to improve access to antibiotics for drug-resistant infections. Since June 2018, sixty-seven webinars have been held with more than 12,600 participants from over 130 countries. At least 10 webinars are planned for 2024.

Some of the most recent [Antimicrobial Viewpoint](#) articles discussed plasmid-mediated resistance in the gonococcus and post-exposure prophylaxis, non-clinical evidence to support streamlined antibiotic development and the PASTEUR Act.

GARDP co-organizes the annual open-access [Antimicrobial Chemotherapy Conference](#) with the British Society of Antimicrobial Chemotherapy and supports other conferences with R&D-focused sessions.

Other resources include the [Antimicrobial Encyclopaedia](#) which comprises definitions of over 260 terms related to antimicrobial R&D, with links to external sources and videos where experts provide further explanations. A new resource will be launched in 2024, the **Antibiotic Discovery and Development Roadmap**. The Roadmap will offer a comprehensive and practical overview of all steps of preclinical and clinical antibiotic development.

Activities delivered through REVIVE are currently supported by 173 experts, of which 91 actively contributed to our content development.

Conclusions

We actively encourage all researchers engaged in antimicrobial R&D, whether new to or experienced in the field, to use our resources, share the materials widely with their networks and help us add more content.